Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of karenitecin versus topotecan in advanced epithelial ovarian cancer
2006-006950-81Phase 3Terminated
- Sponsor
- BioNumerik Pharmaceuticals
- Start
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of karenitecin in epithelial ovarian cancer (EOC) and ovarian cancer (2 arms), sponsored by BioNumerik Pharmaceuticals. Primary endpoint: Progression-free survival. Started Jul 2007; status: terminated.
02
Drugs
karenitecin
03
Conditions
epithelial ovarian cancer (EOC)ovarian cancer
Beyond the preview
Go deeper on 2006-006950-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-006950-81.